Technology
V2X Reports Strong Third Quarter Results with Record Revenue, Net Income, and Adjusted EBITDA
Published
2 years agoon
By
Third Quarter Highlights
Record revenue of $1.08 billion, up 8% y/yIndo-Pacific revenue growth of 31% y/y driven by increased demandOperating income of $49.9 million; Adjusted operating income1 of $76.9 millionRecord net income of $15.1 million, up $21.5 million y/y; Adjusted net income1 of $41.3 million, up 76% y/yRecord adjusted EBITDA1 of $82.7 million, up 28% y/y with a margin of 7.6%Diluted EPS of $0.47; Adjusted diluted EPS1 of $1.29, up 77% y/y
2024 Guidance:
Raising full-year revenue and adjusted EPS1 guidance midpoint and reaffirming adjusted EBITDA and operating cash flow1
MCLEAN, Va., Nov. 4, 2024 /PRNewswire/ — V2X, Inc. (NYSE:VVX) announced third quarter 2024 financial results.
“V2X reported strong third quarter results with record revenue, net income, and adjusted EBITDA1, driven by our continued alignment to well-funded critical missions and the ability to deliver capabilities at scale across the globe,” said Jeremy Wensinger, President and Chief Executive Officer of V2X. “Revenue increased 8% year-over-year and adjusted EBITDA1 increased 28% year-over-year, reflecting strong program performance. Adjusted net income1 increased 76% year-over-year and adjusted diluted EPS1 increased 77% year-over-year.”
Mr. Wensinger continued, “During the third quarter we demonstrated continued growth in the Indo-Pacific region with revenue increasing 31% year-over-year. This performance was tied to the DoD’s continued focus on enhancing U.S. readiness in the region. We are seeing additional opportunities for growth in the region that align to improving the capacity and capabilities of U.S. allies and our partners.”
“Our full spectrum capabilities across the mission lifecycle serve as a differentiator. The fact that we are with our customers across the globe at every phase of mission execution, gives us prodigious knowledge, allowing us to deliver best of breed cost effective solutions that are enhancing outcomes. This unique position is yielding results with V2X securing approximately $5 billion of awards in the third quarter. This includes the $3.7 billion Warfighter-Training Readiness Solutions (W-TRS) award that represents a milestone win for V2X. We delivered a technology enabled solution that was compelling and will ensure every Army soldier has the tools necessary to conduct accurate training preparing them for whenever called upon to deploy. These wins validate our strong positioning in the marketplace and are expected to contribute to our financial performance for years to come.”
Mr. Wensinger concluded, “I believe there is additional opportunity to build on our momentum through further optimization of our business. This includes enhancing the breadth and depth of our pipeline as a result of the collective capabilities. W-TRS is a great example of a solution that leveraged the collective capabilities. We are building on that success to expand our addressable markets in all areas of the company. We are investing in this expanded pipeline to ensure we address opportunities with talent and solutions that will differentiate V2X offerings.”
Third Quarter 2024 Results
“V2X reported record revenue of $1.08 billion in the quarter, which represents 8% year-over-year growth,” said Shawn Mural, Senior Vice President and Chief Financial Officer. “We continued to deliver double digit revenue growth in the Indo-Pacific (31% year-over-year) and Middle East (13% year-over-year) regions, which was achieved through continued expansion of existing business as well as new programs.
“For the quarter, the Company reported operating income of $49.9 million and adjusted operating income1 of $76.9 million. V2X delivered record adjusted EBITDA1, increasing 28% year-over-year to $82.7 million, with a margin of 7.6%, reflecting our expected second half program performance. Third quarter GAAP diluted EPS was $0.47. Adjusted diluted EPS1 for the quarter increased 77% year-over-year to $1.29.”
“Third quarter net cash provided by operating activities was $62.7 million. Adjusted net cash provided by operating activities1 increased 35% year-over-year to $130.1 million. On a year-to-date basis, net cash provided by operating activities was $31.1 million. Adjusted net cash used by operating activities1 was $7.2 million.”
“At the end of the quarter, net debt for V2X was $1,089 million. Net leverage ratio1 was 3.27x, improving 0.29x sequentially. We continue to demonstrate progress on debt paydown and remain on track to be at or below a net leverage ratio of 3.0x, by the end of 2024.”
“Total backlog as of September 27, 2024, was $12.2 billion. Funded backlog was $3.0 billion. Book-to-bill in the quarter was approximately 1.0x. Backlog does not include the full contract value associated with recent awards.”
2024 Guidance
Mr. Mural concluded, “Given our strong performance through the first nine-months of the year we are updating our total year guidance.”
Guidance for 2024 is as follows:
$ millions, except for per share amounts
Prior 2024 Guidance
Updated 2024 Guidance
Revenue
$4,175
$4,275
$4,225
$4,275
Adjusted EBITDA1
$300
$315
$300
$315
Adjusted Diluted Earnings Per Share1
$3.85
$4.20
$3.95
$4.20
Adjusted Net Cash Provided by Operating Activities1
$145
$165
$145
$165
The Company is not providing a quantitative reconciliation with respect to the foregoing forward-looking non-GAAP measures in reliance on the “unreasonable efforts” exception set forth in SEC rules because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. For example, unusual, one-time, non-ordinary, or non-recurring costs, which relate to M&A, integration and related activities cannot be reasonably estimated. Forward-looking statements are based upon current expectations and are subject to factors that could cause actual results to differ materially from those suggested here, including those factors set forth in the Safe Harbor Statement below.
Third Quarter Conference Call
Management will conduct a conference call with analysts and investors at 4:30 p.m. ET on Monday, November 4, 2024. U.S.-based participants may dial in to the conference call at 877-506-6380, while international participants may dial 412-542-4198. A live webcast of the conference call as well as an accompanying slide presentation will be available here: https://app.webinar.net/8eqdGbMZ6Xa
A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through November 18, 2024, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 10193464.
Presentation slides that will be used in conjunction with the conference call will also be made available online in advance on the “investors” section of the company’s website at https://gov2x.com. V2X recognizes its website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with its obligations under the U.S. Securities and Exchange Commission (“SEC”) Regulation FD.
Footnotes:
1 See “Key Performance Indicators and Non-GAAP Financial Measures” for descriptions and reconciliations.
About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.
Investor Contact
Media Contact
Mike Smith, CFA
Angelica Spanos Deoudes
719-637-5773
571-338-5195
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 (the “Act”): Certain material presented herein includes forward-looking statements intended to qualify for the safe harbor from liability established by the Act. These forward-looking statements include, but are not limited to, all the statements and items listed under “2024 Guidance” above and other assumptions contained therein for purposes of such guidance, other statements about our 2024 performance outlook, revenue, contract opportunities, and any discussion of future operating or financial performance.
Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “could,” “potential,” “continue” or similar terminology. These statements are based on the beliefs and assumptions of the management of the Company based on information currently available to management. Forward-looking statements in this press release, include, but are not limited to our discussion regarding the Army and its capabilities; our future performance and capabilities; investing in the expanded pipeline; future net leverage ratio; and our belief in our ability to achieve our updated total year guidance.
These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside our management’s control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Company’s historical experience and our present expectations or projections. For a discussion of some of the risks and uncertainties that could cause actual results to differ from such forward-looking statements, see the risks and other factors detailed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC.
We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
V2X, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (UNAUDITED)
Three Months Ended
Nine Months Ended
September 27,
September 29,
September 27,
September 29,
(In thousands, except per share data)
2024
2023
2024
2023
Revenue
$ 1,081,656
$ 1,001,507
$ 3,164,403
$ 2,922,819
Cost of revenue
990,220
930,828
2,928,858
2,685,910
Selling, general, and administrative expenses
41,549
49,640
127,901
151,021
Operating income
49,887
21,039
107,644
85,888
Loss on extinguishment of debt
—
—
(1,998)
(22,052)
Interest expense, net
(27,152)
(30,252)
(83,533)
(93,946)
Other expense, net
(3,198)
(2,024)
(9,566)
(2,335)
Income (loss) from operations before income taxes
19,537
(11,237)
12,547
(32,445)
Income tax expense (benefit)
4,486
(4,837)
2,896
(10,364)
Net income (loss)
$ 15,051
$ (6,400)
$ 9,651
$ (22,081)
Earnings (loss) per share
Basic
$ 0.48
$ (0.21)
$ 0.31
$ (0.71)
Diluted
$ 0.47
$ (0.21)
$ 0.30
$ (0.71)
Weighted average common shares outstanding – basic
31,550
31,179
31,458
31,048
Weighted average common shares outstanding – diluted
31,973
31,179
31,921
31,048
V2X, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
September 27,
December 31,
(In thousands, except per share data)
2024
2023
Assets
Current assets
Cash, cash equivalents and restricted cash
$ 59,857
$ 72,651
Receivables
766,399
705,995
Prepaid expenses and other current assets
156,042
96,223
Total current assets
982,298
874,869
Property, plant, and equipment, net
65,746
85,429
Goodwill
1,652,855
1,656,926
Intangible assets, net
345,712
407,530
Right-of-use assets
33,370
41,215
Other non-current assets
46,124
15,931
Total non-current assets
2,143,807
2,207,031
Total Assets
$ 3,126,105
$ 3,081,900
Liabilities and Shareholders’ Equity
Current liabilities
Accounts payable
$ 538,225
$ 453,052
Compensation and other employee benefits
115,569
158,088
Short-term debt
16,878
15,361
Other accrued liabilities
235,379
213,700
Total current liabilities
906,051
840,201
Long-term debt, net
1,096,865
1,100,269
Deferred tax liabilities
12,313
11,763
Operating lease liabilities
29,590
34,691
Other non-current liabilities
78,725
104,176
Total non-current liabilities
1,217,493
1,250,899
Total liabilities
2,123,544
2,091,100
Commitments and contingencies (Note 7)
Shareholders’ Equity
Preferred stock; $0.01 par value; 10,000,000 shares authorized; No shares issued and outstanding
—
—
Common stock; $0.01 par value; 100,000,000 shares authorized; 31,556,556 and 31,191,628 shares issued and outstanding as of September 27, 2024 and December 31, 2023, respectively
316
312
Additional paid in capital
766,690
762,324
Retained earnings
240,502
230,851
Accumulated other comprehensive loss
(4,947)
(2,687)
Total shareholders’ equity
1,002,561
990,800
Total Liabilities and Shareholders’ Equity
$ 3,126,105
$ 3,081,900
V2X, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Nine Months Ended
September 27,
September 29,
(In thousands)
2024
2023
Operating activities
Net income (loss)
$ 9,651
$ (22,081)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation expense
16,442
16,532
Amortization of intangible assets
68,252
67,818
Amortization of cloud computing arrangements
2,073
213
Impairment of non-operating long-lived asset
2,192
—
Loss on disposal of property, plant, and equipment
1,170
625
Stock-based compensation
12,874
26,809
Deferred taxes
72
(9,887)
Amortization of debt issuance costs
5,717
6,875
Loss on extinguishment of debt
1,998
22,052
Changes in assets and liabilities:
Receivables
(25,614)
9,647
Other assets
(70,827)
7,916
Accounts payable
66,101
28,094
Compensation and other employee benefits
(42,417)
(28,620)
Other liabilities
(16,581)
9,182
Net cash provided by operating activities
31,103
135,175
Investing activities
Purchases of capital assets
(10,700)
(16,559)
Proceeds from the disposition of assets
14
16
Acquisitions of businesses
(16,939)
—
Distribution from joint venture
—
834
Net cash used in investing activities
(27,625)
(15,709)
Financing activities
Proceeds from issuance of long-term debt
—
250,000
Repayments of long-term debt
(7,669)
(428,763)
Proceeds from revolver
1,009,250
719,750
Repayments of revolver
(1,009,250)
(669,750)
Proceeds from stock awards and stock options
154
7
Payment of debt issuance costs
(1,188)
(7,507)
Prepayment premium on early redemption of debt
—
(1,600)
Payments of employee withholding taxes on stock-based compensation
(8,036)
(17,871)
Net cash used in financing activities
(16,739)
(155,734)
Exchange rate effect on cash
467
(1,540)
Net change in cash, cash equivalents and restricted cash
(12,794)
(37,808)
Cash, cash equivalents and restricted cash – beginning of period
72,651
116,067
Cash, cash equivalents and restricted cash – end of period
$ 59,857
$ 78,259
Supplemental disclosure of cash flow information:
Interest paid
$ 74,774
$ 89,635
Income taxes paid
$ 9,167
$ 5,242
Purchase of capital assets on account
$ 90
$ 2,882
Key Performance Indicators and Non-GAAP Measures
The primary financial performance measures we use to manage our business and monitor results of operations are revenue trends and operating income trends. Management believes that these financial performance measures are the primary drivers for our earnings and net cash from operating activities. Management evaluates its contracts and business performance by focusing on revenue, and operating income. Operating income represents revenue less both cost of revenue and selling, general and administrative (SG&A) expenses. Cost of revenue consists of labor, subcontracting costs, materials, and an allocation of indirect costs, which includes service center transaction costs. SG&A expenses consist of indirect labor costs (including wages and salaries for executives and administrative personnel), bid and proposal expenses and other general and administrative expenses not allocated to cost of revenue.
We manage the nature and amount of costs at the program level, which forms the basis for estimating our total costs and profitability. This is consistent with our approach for managing our business, which begins with management’s assessing the bidding opportunity for each contract and then managing contract profitability throughout the performance period.
In addition to the key performance measures discussed above, we consider adjusted net income, adjusted diluted earnings per share, adjusted operating income, adjusted EBITDA, adjusted EBITDA margin, and adjusted operating cash flow to be useful to management and investors in evaluating our operating performance, and to provide a tool for evaluating our ongoing operations. This information can assist investors in assessing our financial performance and measures our ability to generate capital for deployment among competing strategic alternatives and initiatives. We provide this information to our investors in our earnings releases, presentations, and other disclosures.
Adjusted net income, adjusted diluted earnings per share, adjusted operating income, adjusted EBITDA, adjusted EBITDA margin, and adjusted net cash provided by (used in) operating activities, however, are not measures of financial performance under GAAP and should not be considered a substitute for financial measures determined in accordance with GAAP. Definitions and reconciliations of these items are provided below.
Adjusted operating income is defined as operating income, adjusted to exclude items that may include, but are not limited to, significant charges or credits, and unusual and infrequent non-operating items that impact current results but are not related to our ongoing operations, such as M&A, integration, and related costs.Adjusted EBITDA is defined as operating income, adjusted to exclude depreciation and amortization of intangible assets, and items that may include, but are not limited to, significant charges or credits, and unusual and infrequent non-operating items that impact current results but are not related to our ongoing operations, such as M&A, integration, and related costs.Adjusted EBITDA margin is defined as adjusted EBITDA divided by revenue.Adjusted net income is defined as net income, adjusted to exclude items that may include, but are not limited to, significant charges or credits, and unusual and infrequent non-operating items that impact current results but are not related to our ongoing operations, such as M&A, integration and related costs, amortization of acquired intangible assets, amortization of debt issuance costs, and loss on extinguishment of debt.Adjusted diluted earnings per share is defined as adjusted net income divided by the weighted average diluted common shares outstanding.Cash interest expense, net is defined as interest expense, net adjusted to exclude amortization of debt issuance costs.Adjusted net cash provided by (used in) operating activities or adjusted operating cash flow is defined as net cash provided by (or used in) operating activities adjusted to exclude infrequent non-operating items, such as M&A payments and related costs.Net leverage ratio is defined as net debt (or total debt less unrestricted cash) divided by trailing twelve-month (TTM) bank EBITDA.
Non-GAAP Tables
($K, except per share data)
Three Months Ended
Nine Months Ended
September 27, 2024
September 29, 2023
September 27, 2024
September 29, 2023
Revenue
$ 1,081,656
$ 1,001,507
$ 3,164,403
$ 2,922,819
Net income (loss)
$ 15,051
$ (6,400)
$ 9,651
$ (22,081)
Plus:
Income tax expense (benefit)
4,486
(4,837)
2,896
(10,364)
Other expense, net
3,198
2,024
9,566
2,335
Interest expense, net
27,152
30,252
83,533
93,946
Loss on extinguishment of debt
—
—
1,998
22,052
Operating income
$ 49,887
$ 21,039
$ 107,644
$ 85,888
Plus:
Amortization of intangible assets
22,727
22,607
68,252
67,818
M&A, integration and related costs
4,319
15,824
29,644
41,565
Adjusted operating income
$ 76,933
$ 59,470
$ 205,540
$ 195,271
Plus:
Depreciation and CCA amortization
5,759
5,206
18,515
16,532
Adjusted EBITDA
$ 82,692
$ 64,676
$ 224,055
$ 211,803
Adjusted EBITDA margin
7.6 %
6.5 %
7.1 %
7.2 %
Minus:
Cash interest expense, net
25,598
28,069
77,816
87,071
Income tax expense, as adjusted
6,887
5,937
24,187
26,329
Depreciation and CCA amortization
5,759
5,206
18,515
16,532
Other expense, net, as adjusted
3,198
2,024
7,373
2,335
Adjusted net income
$ 41,250
$ 23,440
$ 96,163
$ 79,536
($K, except per share data)
Three Months Ended
Nine Months Ended
September 27, 2024
September 29, 2023
September 27, 2024
September 29, 2023
Diluted earnings (loss) per share
$ 0.47
$ (0.21)
$ 0.30
$ (0.71)
Plus:
M&A, integration and related costs
0.14
0.37
0.75
0.97
Amortization of intangible assets
0.63
0.52
1.72
1.58
Amortization of debt issuance costs and
Loss on extinguishment of debt
0.05
0.05
0.19
0.67
FMV land impairment
0.00
$ —
0.06
$ —
Adjusted diluted earnings per share
$ 1.29
$ 0.73
$ 3.01
$ 2.51
Average shares outstanding:
Basic, as reported
31,550
31,179
31,458
31,048
Diluted, as reported
31,973
31,179
31,921
31,048
Adjusted diluted
31,973
31,761
31,921
31,520
($K)
Three Months Ended
Nine Months Ended
September 27, 2024
September 29, 2023
September 27, 2024
September 29, 2023
Net cash provided by operating activities
62,654
57,035
31,103
135,175
Plus:
M&A, integration, CARES Act, and related payments
13,009
11,854
25,044
34,248
MARPA facility activity
54,471
27,168
(63,348)
(85,832)
Adjusted operating cash flow
130,134
96,057
(7,201)
83,591
($K)
TTM
September 27, 2024
Net income (loss)
$ 9,159
Plus:
Interest expense, net
112,030
Income tax expense
11,315
Depreciation and amortization
115,248
Additional permitted add-backs1
85,707
TTM Bank EBITDA
$ 333,458
($K, except ratio)
Period Ending
September 27, 2024
Total debt
$ 1,146,490
Cash, cash equivalents and restricted cash
$ 59,857
Less:
Restricted cash
(2,117)
Cash and cash equivalents
$ 57,740
Net debt
$ 1,088,750
TTM bank EBITDA
$ 333,458
Net leverage ratio
3.27x
1Additional permitted add-backs includes among other items, non-cash losses like loss on extinguishment of debt and/or lease impairments, stock compensation, transaction and integration related costs, and pro forma cost savings.
SUPPLEMENTAL INFORMATION
Revenue by client branch, contract type, contract relationship, and geographic region for the periods presented below was as follows:
Revenue by Client
Three Months Ended
Nine Months Ended
September 27,
September 29,
%
September 27,
September 29,
%
(In thousands)
2024
2023
Change
2024
2023
Change
Army
$ 455,877
$ 412,841
10.4 %
$ 1,345,997
$ 1,196,843
12.5 %
Navy
366,217
311,088
17.7 %
1,037,425
896,976
15.7 %
Air Force
121,863
134,728
(9.5) %
367,899
418,710
(12.1) %
Other
137,699
142,850
(3.6) %
413,082
410,290
0.7 %
Total revenue
$ 1,081,656
$ 1,001,507
$ 3,164,403
$ 2,922,819
Revenue by Contract Type
Three Months Ended
Nine Months Ended
September 27,
September 29,
%
September 27,
September 29,
%
(In thousands)
2024
2023
Change
2024
2023
Change
Cost-plus and cost-reimbursable
$ 649,925
$ 570,402
13.9 %
$ 1,850,584
$ 1,589,619
16.4 %
Firm-fixed-price
403,132
402,219
0.2 %
1,229,565
1,237,110
(0.6) %
Time-and-materials
28,599
28,886
(1.0) %
84,254
96,090
(12.3) %
Total revenue
$ 1,081,656
$ 1,001,507
$ 3,164,403
$ 2,922,819
Revenue by Contract Relationship
Three Months Ended
Nine Months Ended
September 27,
September 29,
%
September 27,
September 29,
%
(In thousands)
2024
2023
Change
2024
2023
Change
Prime contractor
$ 1,021,497
$ 945,669
8.0 %
$ 2,972,773
$ 2,740,908
8.5 %
Subcontractor
60,159
55,838
7.7 %
191,630
181,911
5.3 %
Total revenue
$ 1,081,656
$ 1,001,507
$ 3,164,403
$ 2,922,819
Revenue by Geographic Region
Three Months Ended
Nine Months Ended
September 27,
September 29,
%
September 27,
September 29,
%
(In thousands)
2024
2023
Change
2024
2023
Change
United States
$ 604,872
$ 571,405
5.9 %
$ 1,728,480
$ 1,698,689
1.8 %
Middle East
346,527
305,918
13.3 %
1,050,888
866,122
21.3 %
Asia
82,907
63,259
31.1 %
236,371
193,109
22.4 %
Europe
47,350
60,925
(22.3) %
148,664
164,899
(9.8) %
Total revenue
$ 1,081,656
$ 1,001,507
$ 3,164,403
$ 2,922,819
View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-reports-strong-third-quarter-results-with-record-revenue-net-income-and-adjusted-ebitda-302295766.html
SOURCE V2X, Inc.
You may like
Technology
Improve Cell Line Stability From Cloning to GMP Manufacturing, Upcoming Webinar Hosted by Xtalks
Published
30 minutes agoon
October 21, 2026By
In this free webinar, learn how early cell-development decisions can affect cell line stability from cloning through GMP manufacturing. The featured speakers will discuss culture conditions, clone selection, cellular stress, recloning and genetic integrity monitoring, using iPSC development as a key application. Attendees will also explore how image-verified cloning and stronger upstream workflows can support reproducibility, scalable manufacturing and GMP-ready cell banks.
TORONTO, Oct. 21, 2026 /PRNewswire/ — Maintaining cell line stability becomes increasingly important as programs move from early clone development toward scale-up, cell banking and GMP manufacturing. Variability introduced during cloning, culture and expansion can affect genetic integrity, reproducibility and confidence in the cells being carried forward. Using iPSC development as a key application, this webinar will explore how early workflow decisions can help identify and reduce these risks before they impact downstream manufacturing.
The featured panelists will explore how decisions made during clone establishment and early cell development can influence long-term cellular stability. The discussion will examine how culture conditions, media and matrix selection and cellular stress can affect clonal outgrowth and contribute to genetic drift, as well as how stronger clone-selection and monitoring strategies can help reduce these risks.
Using iPSC development as a key application, the speakers will demonstrate how single-cell cloning, image-verified clone selection and automated clonal outgrowth monitoring can provide greater confidence and traceability during cell development. They will also explore when recloning may be appropriate, how genetic integrity can be monitored at key stages and how these approaches can support the creation of robust, well-characterized cell banks.
The session will connect early cell-development decisions with broader goals including reproducibility, scalability, genetic integrity, manufacturing readiness and the development of well-characterized GMP-ready cell banks, giving practical considerations for building more reliable workflows.
Attendees will gain insight into how to recognize sources of clonal variability, strengthen clone-selection strategies, maintain confidence in genetic stability and reduce the risk of carrying early development problems into later stages.
Register for this webinar to learn how cell line stability can be strengthened through clone selection, genetic integrity monitoring and cell-development strategies that support scalable manufacturing.
Join Noud Drummen, Field Application Scientist, Nova Biomedical; and Silvia Rosati, Research Scientist, Process Development Lab, Evotec (Modena), for the live webinar on Thursday, October 29, 2026, at 11am EDT (4pm CET / EU-Central).
For more information, or to register for this event, visit Improve Cell Line Stability From Cloning to GMP Manufacturing.
ABOUT XTALKS
Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.
Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.
To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/
Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: skumar@xtalks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/improve-cell-line-stability-from-cloning-to-gmp-manufacturing-upcoming-webinar-hosted-by-xtalks-302915898.html
SOURCE Xtalks
Technology
Lam Research Corporation Reports Financial Results for the Quarter Ended September 27, 2026
Published
30 minutes agoon
October 21, 2026By
FREMONT, Calif., Oct. 21, 2026 /PRNewswire/ — Lam Research Corporation (the “Company,” “Lam,” “Lam Research”) today announced financial results for the quarter ended September 27, 2026 (the “September 2026 quarter”).
Highlights for the September 2026 quarter were as follows:
Revenue of $8.22 billion.U.S. GAAP gross margin as a percent of revenue of 52.3%, U.S. GAAP operating margin as a percent of revenue of 40.0%, and U.S. GAAP diluted EPS of $2.19.Non-GAAP gross margin as a percent of revenue of 52.4%, non-GAAP operating margin as a percent of revenue of 40.2%, and non-GAAP diluted EPS of $2.20.
Key Financial Data for the Quarters Ended
September 27, 2026 and June 28, 2026
(in thousands, except per share data, percentages, and basis points)
U.S. GAAP
September 2026
June 2026
Change Q/Q
Revenue
$ 8,219,418
$ 6,722,238
+22 %
Gross margin
52.3 %
51.7 %
+ 60 bps
Operating margin
40.0 %
37.4 %
+ 260 bps
Diluted EPS
$ 2.19
$ 1.81
+ 21 %
Non-GAAP
September 2026
June 2026
Change Q/Q
Revenue
$ 8,219,418
$ 6,722,238
+22 %
Gross margin
52.4 %
52.0 %
+ 40 bps
Operating margin
40.2 %
38.4 %
+ 180 bps
Diluted EPS
$ 2.20
$ 1.82
+ 21 %
U.S. GAAP Financial Results
For the September 2026 quarter, revenue was $8.22 billion, gross margin was $4.30 billion, or 52.3% of revenue, operating expenses were $1.02 billion, operating margin was 40.0%, and net income was $2.75 billion, or $2.19 per diluted share on a U.S. GAAP basis. This compares to revenue of $6.72 billion, gross margin of $3.48 billion, or 51.7% of revenue, operating expenses of $965.3 million, operating margin of 37.4%, and net income of $2.28 billion, or $1.81 per diluted share, for the quarter ended June 28, 2026 (the “June 2026 quarter”).
Non-GAAP Financial Results
For the September 2026 quarter, non-GAAP gross margin was $4.31 billion, or 52.4% of revenue, non-GAAP operating expenses were $1.00 billion, non-GAAP operating margin was 40.2%, and non-GAAP net income was $2.77 billion, or $2.20 per diluted share. This compares to non-GAAP gross margin of $3.50 billion, or 52.0% of revenue, non-GAAP operating expenses of $916.4 million, non-GAAP operating margin of 38.4%, and non-GAAP net income of $2.28 billion, or $1.82 per diluted share, for the June 2026 quarter.
“With AI driving higher semiconductor demand and greater device complexity, our focus on operational execution helped Lam deliver record revenue, profit, and earnings per share in the September quarter,” said Tim Archer, Lam Research’s President and Chief Executive Officer. “Our strategic investments in technology inflections and manufacturing capacity are paying off, strengthening our ability to outgrow the wafer fabrication equipment market as the industry expands.”
Balance Sheet and Cash Flow Results
Cash, cash equivalents, and restricted cash balances increased to $7.45 billion at the end of the September 2026 quarter compared to $5.60 billion at the end of the June 2026 quarter. The increase was primarily the result of cash generated from operating activities during the quarter partially offset by cash deployed for capital return activities and capital expenditures.
Deferred revenue at the end of the September 2026 quarter increased to $2.66 billion compared to $2.43 billion as of the end of the June 2026 quarter. Lam’s deferred revenue balance does not include shipments to customers in Japan, to whom control does not transfer until customer acceptance. Shipments to customers in Japan are classified as inventory at cost until the time of acceptance. The estimated future revenue from shipments to customers in Japan was approximately $468.3 million as of September 27, 2026 and $490.2 million as of June 28, 2026.
Revenue
The geographic distribution of revenue during the September 2026 quarter is shown in the following table:
Region
Revenue
China
35 %
Korea
20 %
Taiwan
18 %
Japan
9 %
United States
8 %
Southeast Asia
6 %
Europe
4 %
The following table presents revenue disaggregated between systems and customer support-related revenue:
Three Months Ended
September 27,
2026
June 28,
2026
September 28,
2025
(in thousands)
Systems revenue
$ 5,732,907
$ 4,249,848
$ 3,547,565
Customer support-related revenue and other
2,486,511
2,472,390
1,776,608
$ 8,219,418
$ 6,722,238
$ 5,324,173
Systems revenue includes sales of new leading-edge equipment in deposition, etch, clean, and other wafer fabrication markets.
Customer support-related revenue includes sales of customer services, spares, upgrades, and non-leading-edge equipment from our Reliant® product line.
Outlook
For the quarter ending December 27, 2026, Lam is providing the following guidance:
U.S. GAAP
Reconciling Items
Non-GAAP
Revenue
$8.60 Billion
+/-
$400 Million
—
$8.60 Billion
+/-
$400 Million
Gross margin
52.5 %
+/-
1 %
$ 2.7
Million
52.5 %
+/-
1 %
Operating margin
40.5 %
+/-
1 %
$ 3.0
Million
40.5 %
+/-
1 %
Net income per diluted share
$2.33
+/-
$0.15
$ 3.3
Million
$2.33
+/-
$0.15
Diluted share count
1.253 Billion
—
1.253 Billion
The information provided above is only an estimate of what the Company believes is realizable as of the date of this release and does not incorporate the potential impact of any business combinations, asset acquisitions, divestitures, restructuring, balance sheet valuation adjustments, financing arrangements, other investments, or other items that may be completed or realized after the date of this release, except as described below. U.S. GAAP to non-GAAP reconciling items provided include only those items that are known and can be estimated as of the date of this release. Actual results will vary from this model and the variations may be material. Reconciling items included above are as follows:
Gross margin – amortization related to intangible assets acquired through certain business combinations, $2.7 million.Operating margin – amortization related to intangible assets acquired through certain business combinations, $3.0 million.Net income per diluted share – amortization related to intangible assets acquired through certain business combinations, $3.0 million; amortization of note discounts, $0.5 million; and associated tax benefit for non-GAAP items ($0.2 million); totaling $3.3 million.
Use of Non-GAAP Financial Results
In addition to U.S. GAAP results, this press release also contains non-GAAP financial results. The Company’s non-GAAP results for both the September 2026 and June 2026 quarters exclude amortization related to intangible assets acquired through certain business combinations, the effects of elective deferred compensation-related assets and liabilities, amortization of note discounts, and the net income tax effect of non-GAAP items. The September 2026 quarter also excludes the net income tax effect of a change in tax law, and the June 2026 quarter excludes workforce optimization charges and the related income tax effect.
Management uses non-GAAP gross margin, operating expense, operating income, operating margin, net income, and net income per diluted share to evaluate the Company’s operating and financial results. The Company believes the presentation of non-GAAP results is useful to investors for analyzing business trends and comparing performance to prior periods, along with enhancing investors’ ability to view the Company’s results from management’s perspective. Tables presenting reconciliations of non-GAAP results to U.S. GAAP results are included at the end of this press release and on the Company’s website at https://investor.lamresearch.com.
Caution Regarding Forward-Looking Statements
Statements made in this press release that are not of historical fact are forward-looking statements and are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning: our outlook and guidance for future financial results, including revenue, gross margin, operating margin, net income per diluted share, and diluted share count; AI-driven semiconductor demand and device complexity; our focus on operational execution; the perceived benefits of our strategic investments; our ability to outgrow the wafer fabrication equipment market as the industry expands; and deferred revenue. These statements are not a guarantee of future performance and involve a number of risks, uncertainties, and other factors that could cause our actual results or outcomes, or the timing of our results or outcomes, to differ materially from those expressed or implied in this press release. Such risks, uncertainties, and other factors include: our assumptions related to continued expansion of the wafer fabrication equipment market, growth of deposition and etch intensity, and scaling of our operations may prove invalid; business, economic, political, and/or regulatory conditions in the consumer electronics industry, the semiconductor industry and the overall economy, including wafer fabrication equipment spending or demand related to AI, may deteriorate or change; the actions, performance, or investment levels of our customers and competitors may be inconsistent with our expectations; customer and product mix, including across market segments and geographical regions, may change; we may be unable to realize the value of our products and technology, successfully commercialize new products and technologies, implement pricing initiatives, or execute on perceived opportunities; we may be unable to achieve anticipated operational, manufacturing, supply chain, procurement, and scale efficiencies; customer technology transitions, capacity expansions, and fab construction projects may have different timing or be less successful than we expect; we may be unable to manage operating expenses effectively while continuing to invest in research and development, product innovation, customer support, and future growth opportunities; trade regulations, export controls (including entity listings, end use/user controls, technology controls, and foreign direct product rules), tariffs, trade disputes, and other geopolitical developments may inhibit our ability to sell our products or services; supply chain cost increases, tariffs, and other inflationary pressures may continue to impact our profitability; supply chain disruptions or manufacturing capacity constraints may limit our ability to manufacture and sell our products; natural and human-caused disasters, disease outbreaks, war, terrorism, political or governmental unrest or instability, or other events beyond our control may impact our operations and revenue in affected areas; as well as the other risks and uncertainties that are described in the documents filed or furnished by us with the Securities and Exchange Commission, including specifically the “Risk Factors” described in our most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. You should evaluate all forward-looking statements made in this press release in the context of these risks, uncertainties, and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on our current beliefs, expectations, and assumptions about future events. Except as required by law, we undertake no obligation to update the information or statements made in this press release.
Lam Research Corporation is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam’s equipment and services allow customers to build smaller and better performing devices. In fact, today, nearly every advanced chip is built with Lam technology. We combine superior systems engineering, technology leadership, and a strong values-based culture, with an unwavering commitment to our customers. Lam Research (Nasdaq: LRCX) is a FORTUNE 500® company headquartered in Fremont, Calif., with operations around the globe. Learn more at www.lamresearch.com. (LRCX)
Condensed Consolidated Financial Tables Follow.
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data and percentages)
(unaudited)
Three Months Ended
September 27,
2026
June 28,
2026
September 28,
2025
Revenue
$ 8,219,418
$ 6,722,238
$ 5,324,173
Cost of goods sold
3,920,565
3,243,498
2,639,294
Gross margin
4,298,853
3,478,740
2,684,879
Gross margin as a percent of revenue
52.3 %
51.7 %
50.4 %
Research and development
666,398
642,922
576,446
Selling, general and administrative
348,728
322,330
279,345
Total operating expenses
1,015,126
965,252
855,791
Operating income
3,283,727
2,513,488
1,829,088
Operating margin
40.0 %
37.4 %
34.4 %
Other income (expense), net
28,493
41,654
30,074
Income before income taxes
3,312,220
2,555,142
1,859,162
Income tax expense
(559,082)
(277,860)
(290,502)
Net income
$ 2,753,138
$ 2,277,282
$ 1,568,660
Net income per share:
Basic
$ 2.20
$ 1.82
$ 1.24
Diluted
$ 2.19
$ 1.81
$ 1.24
Number of shares used in per share calculations:
Basic
1,250,883
1,251,286
1,264,446
Diluted
1,255,768
1,256,032
1,269,313
Cash dividend declared per common share
$ 0.33
$ 0.26
$ 0.26
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
September 27,
2026
June 28,
2026
September 28,
2025
(unaudited)
(1)
(unaudited)
ASSETS
Cash and cash equivalents
$ 7,437,384
$ 5,579,171
$ 6,693,046
Accounts receivable, net
5,658,379
5,339,682
3,633,034
Inventories
4,550,544
4,276,111
4,095,054
Prepaid expenses and other current assets
477,805
415,741
385,580
Total current assets
18,124,112
15,610,705
14,806,714
Property and equipment, net
3,126,029
2,956,472
2,510,531
Goodwill and intangible assets
1,911,547
1,895,859
1,826,950
Other assets
3,191,368
3,066,707
2,756,016
Total assets
$ 26,353,056
$ 23,529,743
$ 21,900,211
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current portion of long-term debt and finance lease obligations
$ 3,486
$ 4,073
$ 754,363
Other current liabilities
7,309,013
5,933,176
5,953,547
Total current liabilities
7,312,499
5,937,249
6,707,910
Long-term debt and finance lease obligations
3,731,958
3,730,490
3,729,580
Income taxes payable
684,273
681,197
646,044
Other long-term liabilities
715,852
709,886
623,925
Total liabilities
12,444,582
11,058,822
11,707,459
Stockholders’ equity (2)
13,908,474
12,470,921
10,192,752
Total liabilities and stockholders’ equity
$ 26,353,056
$ 23,529,743
$ 21,900,211
(1)
Derived from audited financial statements.
(2)
Common shares issued and outstanding were 1,249,145 as of September 27, 2026, 1,251,278 as of June 28, 2026, and 1,259,176 as of September 28, 2025.
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)
Three Months Ended
September 27,
2026
June 28,
2026
September 28,
2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
$ 2,753,138
$ 2,277,282
$ 1,568,660
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
122,072
119,642
101,644
Deferred income taxes
(55,300)
(175,752)
(62,875)
Equity-based compensation expense
114,696
103,985
97,241
Other, net
27,633
(8,006)
(1,890)
Changes in operating assets and liabilities
535,413
(859,923)
76,184
Net cash provided by operating activities
3,497,652
1,457,228
1,778,964
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures and intangible assets
(257,697)
(188,801)
(185,121)
Other, net
(9,292)
45,060
(927)
Net cash used for investing activities
(266,989)
(143,741)
(186,048)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on debt, including finance lease obligations and payments for debt issuance costs
(34,489)
(1,355)
(1,417)
Treasury stock purchases, including excise tax payments
(1,024,965)
(246,560)
(975,791)
Dividends paid
(325,402)
(325,318)
(291,981)
Reissuance of treasury stock related to employee stock purchase plan
—
88,780
—
Proceeds from issuance of common stock, net of issuance costs
4,263
4,426
—
Other, net
(1,786)
(282)
(12,449)
Net cash used for financing activities
(1,382,379)
(480,309)
(1,281,638)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
4,663
(2,056)
(7,059)
Net change in cash, cash equivalents, and restricted cash
1,852,947
831,122
304,219
Cash, cash equivalents, and restricted cash at beginning of period (1)
5,597,943
4,766,821
6,407,656
Cash, cash equivalents, and restricted cash at end of period (1)
$ 7,450,890
$ 5,597,943
$ 6,711,875
(1)
Restricted cash is reported within Other assets in the Condensed Consolidated Balance Sheets.
Non-GAAP Financial Summary
(in thousands, except percentages and per share data)
(unaudited)
Three Months Ended
September 27,
2026
June 28,
2026
Revenue
$ 8,219,418
$ 6,722,238
Gross margin
$ 4,305,019
$ 3,497,336
Gross margin as a percent of revenue
52.4 %
52.0 %
Operating expenses
$ 1,004,280
$ 916,420
Operating income
$ 3,300,739
$ 2,580,916
Operating margin
40.2 %
38.4 %
Net income
$ 2,768,417
$ 2,279,968
Net income per diluted share
$ 2.20
$ 1.82
Shares used in per share calculation – diluted
1,255,768
1,256,032
Reconciliation of U.S. GAAP Net Income to Non-GAAP Net Income
(in thousands, except per share data)
(unaudited)
Three Months Ended
September 27,
2026
June 28,
2026
U.S. GAAP net income
$ 2,753,138
$ 2,277,282
Pre-tax non-GAAP items:
Amortization related to intangible assets acquired through certain business combinations – cost of goods sold
2,668
2,668
Elective deferred compensation (“EDC”) related liability valuation increase – cost of goods sold
3,498
15,379
Workforce optimization charges – cost of goods sold
—
549
EDC related liability valuation increase – research and development
6,299
27,682
Workforce optimization charges – research and development
—
960
Amortization related to intangible assets acquired through certain business combinations – selling, general and administrative
348
348
EDC related liability valuation increase – selling, general and administrative
4,199
18,454
Workforce optimization charges – selling, general and administrative
—
1,388
Amortization of note discounts – other income (expense), net
508
504
Gain on EDC related asset – other income (expense), net
(12,870)
(61,325)
Net income tax benefit on non-GAAP items
(825)
(3,921)
Income tax expense from a change in tax law
11,454
—
Non-GAAP net income
$ 2,768,417
$ 2,279,968
Non-GAAP net income per diluted share
$ 2.20
$ 1.82
U.S. GAAP net income per diluted share
$ 2.19
$ 1.81
U.S. GAAP and non-GAAP number of shares used for per diluted share calculation
1,255,768
1,256,032
Reconciliation of U.S. GAAP Gross Margin, Operating Expenses and Operating Income to Non-GAAP Gross Margin,
Operating Expenses and Operating Income
(in thousands, except percentages)
(unaudited)
Three Months Ended
September 27,
2026
June 28,
2026
U.S. GAAP gross margin
$ 4,298,853
$ 3,478,740
Pre-tax non-GAAP items:
Amortization related to intangible assets acquired through certain business combinations
2,668
2,668
EDC related liability valuation increase
3,498
15,379
Workforce optimization charges
—
549
Non-GAAP gross margin
$ 4,305,019
$ 3,497,336
U.S. GAAP gross margin as a percent of revenue
52.3 %
51.7 %
Non-GAAP gross margin as a percent of revenue
52.4 %
52.0 %
U.S. GAAP operating expenses
$ 1,015,126
$ 965,252
Pre-tax non-GAAP items:
Amortization related to intangible assets acquired through certain business combinations
(348)
(348)
EDC related liability valuation increase
(10,498)
(46,136)
Workforce optimization charges
—
(2,348)
Non-GAAP operating expenses
$ 1,004,280
$ 916,420
U.S. GAAP operating income
$ 3,283,727
$ 2,513,488
Non-GAAP operating income
$ 3,300,739
$ 2,580,916
U.S. GAAP operating margin
40.0 %
37.4 %
Non-GAAP operating margin
40.2 %
38.4 %
Lam Research Corporation Contacts:
Ram Ganesh, Investor Relations, phone: 510-572-1615, e-mail: investor.relations@lamresearch.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lam-research-corporation-reports-financial-results-for-the-quarter-ended-september-27-2026-302915810.html
SOURCE Lam Research Corporation
Technology
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026
Published
30 minutes agoon
October 21, 2026By
SALT LAKE CITY, Oct. 21, 2026 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report its third quarter fiscal year 2026 financial results on Wednesday, November 4, 2026, after market close. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
Conference Call Details:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link: https://app.webinar.net/wK8exGQrE0B
Live audio of the webcast will be available on the Investors page of the Company’s website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks’ gestation and is the leading cause of illness and death in newborns. The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, marking the longest stretch of the lowest grade in Report Card history. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman’s individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date, time and content of the Company’s quarterly earnings release and conference call; availability of the live audio of the conference call on the Company’s website; and the Company’s strategic directives under the caption “About Sera Prognostics, Inc.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading “Risk Factors” contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-third-quarter-fiscal-year-2026-financial-results-on-november-4-2026-302915767.html
SOURCE Sera Prognostics, Inc.
Improve Cell Line Stability From Cloning to GMP Manufacturing, Upcoming Webinar Hosted by Xtalks
Lam Research Corporation Reports Financial Results for the Quarter Ended September 27, 2026
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoHighland and Bath Counties, Virginia Go Live on a Shared Caliber Hosted CAD Environment
-
Technology4 days agoJinkoSolar Unveils Tiger Neo 5.0 All-Black Residential Solar Module with 25.52% Efficiency
-
Near Videos5 days agoWhat if you could build a skyscraper with one prompt?
-
Technology4 days agoBioethanol from human hair – Indian start-up’s solution to rising prices of grains and sugar
-
Technology3 days agoGMIF2026: AI Inference Powers the “Token Factory” and Drives System-Level Rethinking of Memory & Storage
-
Technology3 days agoLinktel Technologies Highlights Breakthrough 1.6T LPO Performance & Strong Market Pull at OCP 2026
-
Technology3 days agoTruecaller announces preliminary numbers for the third quarter 2026
-
Coin Market2 days agoWorld Liberty’s USD1 stablecoin sheds $400M in market cap in two weeks